Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus

Expert Opinion on Drug Metabolism & Toxicology
Natasha Jordan, David P D'Cruz

Abstract

Systemic lupus erythematosus (SLE) is a severe autoimmune disease and a sizeable proportion of patients remain refractory to currently available immunosuppressive agents. The burden of uncontrolled disease is significant as disease flare and persistent inflammation lead to long-term damage accrual and increased morbidity. Belimumab , a humanized monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), is the first drug to be approved by the US FDA for the treatment of SLE in 50 years. In this review, we provide an overview of novel therapeutic agents under development for the treatment of SLE, a description of the pharmacodynamic and pharmacokinetic properties of belimumab, evidence of efficacy of belimumab as demonstrated in clinical trials, safety and tolerability data and a summary of ongoing clinical trials of belimumab in SLE. This information was amassed following a comprehensive MEDLINE and Cochrane library search. Ongoing clinical trial information was obtained from ClinicalTrials.gov. Two, large Phase III trials have demonstrated the clinical efficacy of belimumab in musculoskeletal, mucocutaneous, haematologic and constitutional features of SLE. Patients with severe disease manifestations such as lupus nephri...Continue Reading

References

Nov 24, 1999·Lupus·M Y KimR E Shore
Dec 10, 1999·The Journal of Experimental Medicine·F MackayJ L Browning
Oct 18, 2002·Arthritis and Rheumatism·Maria J LeandroDavid A Isenberg
Jan 15, 2003·Annals of the Rheumatic Diseases·X MarietteR Kimberly
Mar 5, 2004·The New England Journal of Medicine·Gabriel ContrerasDavid Roth
Aug 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Meera RamanujamAnne Davidson
Feb 25, 2005·Journal of the American Society of Nephrology : JASN·Tak-Mao ChanUNKNOWN Hong Kong Nephrology Study Group
May 10, 2005·Arthritis and Rheumatism·S BernatskyA Clarke
Nov 25, 2005·The New England Journal of Medicine·Ellen M GinzlerGerald B Appel
Feb 18, 2006·The Journal of Clinical Investigation·Meera RamanujamAnne Davidson
Jul 27, 2006·Arthritis and Rheumatism·S BernatskyR Ramsey-Goldman
Aug 18, 2006·Seminars in Immunology·Claudia Bossen, Pascal Schneider
Apr 17, 2009·Journal of the American Society of Nephrology : JASN·Gerald B AppelUNKNOWN Aspreva Lupus Management Study Group
Aug 29, 2009·Arthritis and Rheumatism·Mandana NikpourDafna D Gladman
Aug 29, 2009·Arthritis and Rheumatism·Richard A FurieWilliam W Freimuth
Sep 14, 2010·Annals of the Rheumatic Diseases·Frédéric A HoussiauUNKNOWN MAINTAIN Nephritis Trial Group
Feb 18, 2012·Annals of the Rheumatic Diseases·Ronald F van VollenhovenWilliam Freimuth
Mar 27, 2013·Arthritis and Rheumatism·David WofsyBetty Diamond
Nov 5, 2013·The Journal of Rheumatology·Ellen M GinzlerUNKNOWN LBSL02/99 Study Group

❮ Previous
Next ❯

Citations

Mar 4, 2017·Expert Opinion on Emerging Drugs·Abdulgabar Salama
Jul 18, 2018·Stem Cells International·Mengyuan WangLiang Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.